Edesa CEO granted 2,578 restricted share units
Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech, Inc. reported that Chief Executive Officer Pardeep Nijhawan received a grant of 2,578 restricted share units on April 1, 2026, which vested in full upon grant under the 2019 Equity Incentive Compensation Plan. Following this award, he directly holds 631,391 common shares, with additional indirect holdings reported through several affiliated entities and a family trust.
Insider Trade Summary
Grant/Award: 2,578 shares
Grant/Award
1 txn
Insider
Nijhawan Pardeep
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Shares | 2,578 | $0.00 | $0.00 |
| Holding | Common Shares | -- | -- | -- |
| Holding | Common Shares | -- | -- | -- |
| Holding | Common Shares | -- | -- | -- |
| Holding | Common Shares | -- | -- | -- |
Holdings After Transaction:
Common Shares — 631,391 shares (Direct);
Common Shares — 402,702 shares (Indirect, Held by Pardeep Nijhawan Medicine Professional Corporation);
Common Shares — 32,609 shares (Indirect, Held by The New Nijhawan Family Trust 2015);
Common Shares — 32,013 shares (Indirect, Held by The Digestive Health Clinic Inc.);
Common Shares — 53,104 shares (Indirect, Held by 1968160 Ontario Inc.)
Footnotes (3)
- F1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.
- F2. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F3. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Key Figures
Restricted share unit grant: 2,578 units
Award price per share: $0.0000 per share
Direct holdings after grant: 631,391 shares
+4 more
7 metrics
Restricted share unit grant
2,578 units
Award to CEO on April 1, 2026
Award price per share
$0.0000 per share
Restricted share unit grant
Direct holdings after grant
631,391 shares
CEO common shares after April 1, 2026 transaction
Indirect holdings – Pardeep Nijhawan Medicine Professional Corporation
402,702 shares
Common shares held indirectly
Indirect holdings – New Nijhawan Family Trust 2015
32,609 shares
Common shares held indirectly
Indirect holdings – The Digestive Health Clinic Inc.
32,013 shares
Common shares held indirectly
Indirect holdings – 1968160 Ontario Inc.
53,104 shares
Common shares held indirectly
Key Terms
restricted share units, 2019 Equity Incentive Compensation Plan, pecuniary interest, beneficial ownership, +1 more
5 terms
2019 Equity Incentive Compensation Plan financial
"vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"
pecuniary interest financial
"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"
beneficial ownership financial
"shall not be deemed an admission of beneficial ownership of all of the reported shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
wholly-owned financial
"Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person"
A wholly-owned business is one that is 100% owned by another company, meaning the parent holds all shares and controls decisions. For investors, this matters because the parent company must include the wholly-owned business’s results and liabilities in its own financial picture, so any profits, losses or risks from that unit directly affect the parent’s value—like owning an entire rental property rather than sharing it with partners.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Edesa Biotech (EDSA) report for its CEO?
Edesa Biotech reported that CEO Pardeep Nijhawan received 2,578 restricted share units on April 1, 2026. These units vested immediately and increased his direct common share holdings to 631,391, according to the company’s 2019 Equity Incentive Compensation Plan.
What is the size and nature of the equity award to Edesa Biotech’s CEO?
The CEO received 2,578 restricted share units with a reported price of $0.0000 per unit. A footnote explains this reflects a grant under Edesa Biotech’s 2019 Equity Incentive Compensation Plan and that the units vested in full immediately upon grant.
Is the April 1, 2026 Edesa Biotech Form 4 a market purchase or sale?
No, the primary transaction is a compensation-related grant coded “A” for an award or other acquisition. It represents 2,578 restricted share units that vested upon grant, rather than an open-market purchase or sale of Edesa Biotech common shares.
What compensation plan governed the CEO’s equity grant at Edesa Biotech?
The grant of 2,578 restricted share units to Edesa Biotech’s CEO was made under the company’s 2019 Equity Incentive Compensation Plan. The footnote states that these restricted share units vested in full upon grant, indicating an immediately realized equity award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
